The Latin America, Middle East and Africa Genotyping Market is expected to witness market growth of 18.1% CAGR during the forecast period (2022-2028).
SNPs (single nucleotide polymorphisms) are alterations in DNA that occur at specific locations within the genome. For example, most people have a C nucleotide at a given base location in their genome, whereas a small percentage of people have an A. It indicates that there is an SNP with two potential nucleotide changes at this exact position, C or A. The human genome contains over 660 million SNPs, making them the most prevalent type of genetic differences in humans. Traits such as eye color and hereditary diseases like cystic fibrosis and sickle cell anemia, as well as serve as markers for the development of complicated diseases like diabetes and Alzheimer's disease.
By forecasting an individual's likelihood of acquiring specific diseases or designing targeted medicines tailored to the disease's genetic foundation, SNP genotyping can help usher in a new era of personalized medicine. SNP-based tests could aid in the selection of the appropriate treatment course because SNPs are linked to individual therapeutic responses.
During the first peak of the local COVID-19 outbreak, to figure out where SARS-CoV-2 came from and how it spread and evolved in the United Arab Emirates. They discovered a global clade distribution as well as eleven novel genetic variants that were nearly unknown elsewhere and designated five subclades unique to the UAE virus population. Human-to-human transmission across settlements was linked to local business activity.
The United Arab Emirates (UAE) is the first nation to authorize a Chinese COVID-19 vaccine. It is one of the world's most well-known international business and tourist centers. Even though the pandemic lasted for a long time, only a few SARS-CoV-2 samples were sequenced, and the virus's transmission and evolution trends in this area are unknown. On January 29th, 2020, the first case of SARS-CoV-2 was discovered in the country.
The Brazil market dominated the LAMEA Genotyping Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $630.4 million by 2028. The Argentina market is poised to grow at a CAGR of 18.7% during (2022 - 2028). Additionally, The UAE market is expected to display a CAGR of 17.8% during (2022 - 2028).
Based on Product, the market is segmented into Reagents & Kits, Instruments, and Software & Services. Based on Application, the market is segmented into Diagnostics & Personalized Medicine, Agricultural Biotechnology, Pharmacogenomics, Animal Genetics, and Others. Based on End Use, the market is segmented into Diagnostics & Research Laboratories, Pharmaceutical & Biopharmaceutical Companies, Academic Institutes, and Others. Based on Technology, the market is segmented into PCR, Sequencing, Capillary Electrophoresis, Microarray, Mass Spectrometry, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd., Danaher Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Eurofins Scientific Group, and Fluidigm Corporation.
SNPs (single nucleotide polymorphisms) are alterations in DNA that occur at specific locations within the genome. For example, most people have a C nucleotide at a given base location in their genome, whereas a small percentage of people have an A. It indicates that there is an SNP with two potential nucleotide changes at this exact position, C or A. The human genome contains over 660 million SNPs, making them the most prevalent type of genetic differences in humans. Traits such as eye color and hereditary diseases like cystic fibrosis and sickle cell anemia, as well as serve as markers for the development of complicated diseases like diabetes and Alzheimer's disease.
By forecasting an individual's likelihood of acquiring specific diseases or designing targeted medicines tailored to the disease's genetic foundation, SNP genotyping can help usher in a new era of personalized medicine. SNP-based tests could aid in the selection of the appropriate treatment course because SNPs are linked to individual therapeutic responses.
During the first peak of the local COVID-19 outbreak, to figure out where SARS-CoV-2 came from and how it spread and evolved in the United Arab Emirates. They discovered a global clade distribution as well as eleven novel genetic variants that were nearly unknown elsewhere and designated five subclades unique to the UAE virus population. Human-to-human transmission across settlements was linked to local business activity.
The United Arab Emirates (UAE) is the first nation to authorize a Chinese COVID-19 vaccine. It is one of the world's most well-known international business and tourist centers. Even though the pandemic lasted for a long time, only a few SARS-CoV-2 samples were sequenced, and the virus's transmission and evolution trends in this area are unknown. On January 29th, 2020, the first case of SARS-CoV-2 was discovered in the country.
The Brazil market dominated the LAMEA Genotyping Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $630.4 million by 2028. The Argentina market is poised to grow at a CAGR of 18.7% during (2022 - 2028). Additionally, The UAE market is expected to display a CAGR of 17.8% during (2022 - 2028).
Based on Product, the market is segmented into Reagents & Kits, Instruments, and Software & Services. Based on Application, the market is segmented into Diagnostics & Personalized Medicine, Agricultural Biotechnology, Pharmacogenomics, Animal Genetics, and Others. Based on End Use, the market is segmented into Diagnostics & Research Laboratories, Pharmaceutical & Biopharmaceutical Companies, Academic Institutes, and Others. Based on Technology, the market is segmented into PCR, Sequencing, Capillary Electrophoresis, Microarray, Mass Spectrometry, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd., Danaher Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Eurofins Scientific Group, and Fluidigm Corporation.
Scope of the Study
Market Segments Covered in the Report:
By Product
- Reagents & Kits
- Instruments
- Software & Services
By Application
- Reagents & Kits
- Instruments
- Software & Services
By End Use
- Diagnostics & Research Laboratories
- Pharmaceutical & Biopharmaceutical Companies
- Academic Institutes
- Others
By Technology
- PCR
- Sequencing
- Capillary Electrophoresis
- Microarray
- Mass Spectrometry
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Agilent Technologies, Inc.
- Thermo Fisher Scientific, Inc.
- Qiagen N.V.
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- Eurofins Scientific Group
- Fluidigm Corporation
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. LAMEA Genotyping Market by Product
Chapter 5. LAMEA Genotyping Market by Application
Chapter 6. LAMEA Genotyping Market by End Use
Chapter 7. LAMEA Genotyping Market by Technology
Chapter 8. LAMEA Genotyping Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Agilent Technologies, Inc.
- Thermo Fisher Scientific, Inc.
- Qiagen N.V.
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- Eurofins Scientific Group
- Fluidigm Corporation
Methodology
LOADING...
